

~ PLEASE PRINT LEGIBLY ~

Name _____
Credentials/Degree _____
Mailing Address _____ _____
Last 4 digits of SS# _____
Signature _____

**Addressing the Clinical  
Challenge of Inadequate  
Response in Patients With  
Rheumatoid Arthritis  
(#EM0516B)  
Continuing Medical Education  
Posttest**

1. An adequate treatment response in patients with RA is typically assessed by monitoring which of the following?
  - A. Disease activity
  - B. Radiographic progression
  - C. Functional response
  - D. All of the above
  
2. Which of the following is true about defining an inadequate response to therapy?
  - A. It has been clearly defined in clinical trials and should be used to guide practice
  - B. It can be defined as persistent tender and swollen joints after less than 3 months of methotrexate therapy
  - C. The same definition can be used whether the patient is receiving methotrexate or a biologic therapy
  - D. It can be defined as continued clinical symptoms (tender and swollen joints), radiographic progression, and/or limited function
  
3. Which of the following types of outcome measures have been shown to be the most useful guide for assessing and subsequently modifying therapy?
  - A. Monitoring radiographic progression
  - B. Composite scores, such as DAS
  - C. Functional scores, such as HAQ
  - D. All of the above

4. Changes in which of the following laboratory tests may be useful in predicting response to therapy?
  - A. Anti-CCP
  - B. Rheumatoid factor
  - C. CRP/ESR
  - D. CBC
  
5. Results from a variety of clinical trials suggest that in patients with an inadequate response to methotrexate, a TNF inhibitor should be administered:
  - A. In combination with methotrexate
  - B. As monotherapy
  - C. In combination with another TNF inhibitor
  - D. None of the above
  
6. In some trials, inadequate response has been defined as at least how many months of TNF inhibitor therapy without improvement in clinical parameters?
  - A. 3 months
  - B. 6 months
  - C. 9 months
  - D. 12 months
  
7. Which of the following is NOT a reasonable conclusion from recently reported trials of rituximab (used in combination with methotrexate)?
  - A. Rituximab is expected to improve disease symptoms, functionality, and quality of life
  - B. Benefits were observed even in patients who had failed multiple therapies
  - C. Benefits with rituximab may be maintained for at least 24 weeks
  - D. Rituximab can be safely combined with another biologic DMARD

8. All of the following are true statements about the treatment of patients with an inadequate response to RA therapy EXCEPT:
- A. Introduction of additional therapy should take place as soon as it is apparent that methotrexate alone will be inadequate
  - B. There may be a disconnect between clinical response measures and radiographic changes
  - C. Increasing the frequency of infliximab dosing may improve response
  - D. Adding etanercept to infliximab does not improve the likelihood of a good response

## **EVALUATION**

### **Addressing the Clinical Challenge of Inadequate Response in Patients With Rheumatoid Arthritis (#EM0516B)**

Please circle one option for each of the following questions.

1) The overall quality of this activity and its educational content was excellent.

- a) Strongly agree      b) Agree      c) Undecided      d) Disagree
- e) Strongly disagree

2) Upon completion of this activity I am better able to:

Describe the clinical implications of inadequate response to therapy for patients with RA.

- a) Strongly agree      b) Agree      c) Undecided      d) Disagree
- e) Strongly disagree

Summarize the challenge of defining inadequate response and how this definition may be different depending on current therapy.

- a) Strongly agree      b) Agree      c) Undecided      d) Disagree
- e) Strongly disagree

Evaluate individual response to therapy and alter RA treatment plans to achieve tight disease control.

- a) Strongly agree      b) Agree      c) Undecided      d) Disagree
- e) Strongly disagree

3) The information given was without promotional or commercial bias.

- a) Strongly agree      b) Agree      c) Undecided      d) Disagree
- e) Strongly disagree

4) The scientific articles provided something new that I will apply to my practice.  
a) Strongly agree      b) Agree      c) Undecided      d) Disagree  
e) Strongly disagree

5) The content met my educational needs.  
a) Strongly agree      b) Agree      c) Undecided      d) Disagree  
e) Strongly disagree

6) I would recommend this activity to others.  
a) Strongly agree      b) Agree      c) Undecided      d) Disagree  
e) Strongly disagree

Suggestions/comments regarding this material, or recommendations for future presentations:

---

---

---

---

---

---

---

---

Credit for this activity is available until February 2009.

**To receive a maximum of 1 *AMA PRA Category 1 Credit(s)*<sup>™</sup>, complete post-test with passing score (70% or better) and return post-test and evaluation to:**

**UT Southwestern Medical Center  
Continuing Medical Education/ Enduring Materials  
5323 Harry Hines Blvd.  
Dallas, Texas 75390-9059**

**Or fax to 214-648-2317**

**Certificate will be mailed 4 to 6 weeks after receipt of requested items.**